title: Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients.
abstract: OBJECTIVE
  To identify potential prognostic factors and criteria for early detection of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1 (NF1).
  
  
  METHODS
  Retrospective study of malignant peripheral nerve sheath tumors in a cohort of 395 patients with NF1 followed up between October 1, 1988, and January 1, 1999; review of the clinical and histological characteristics of treatment and course; and analysis of p53 mutations and overexpression in tumors.
  
  
  METHODS
  Teaching hospital referral neurofibromatosis center for adults.
  
  
  METHODS
  Seventeen patients with NF1 (9 males and 8 females). Mean +/- SD patient age at diagnosis was 32 +/- 14 years.
  
  
  METHODS
  (1) Clinical symptoms, (2) comparison of p53 mutations and overexpression in benign vs malignant tumors; and (3) median survival.
  
  
  RESULTS
  Twelve patients had high-grade tumors. All tumors except 1 developed on preexisting nodular or plexiform neurofibromas. Pain and enlarging mass were the first and predominant signs. None of the benign tumors displayed significant p53 staining or p53 mutations. Six of 12 malignant tumors significantly overexpressed p53, and 4 of 6 harbored p53 missense mutations. Median survival was 18 months overall, 53 months in peripheral locations, and 21 months in axial locations.
  
  
  CONCLUSIONS
  Malignant peripheral nerve sheath tumors are highly aggressive in NF1. They mostly arise from plexiform or nodular neurofibromas. Investigations and deep biopsy of painful and enlarging nodular or plexiform neurofibromas should be considered in patients with NF1. Late appearance of p53 mutations and overexpression precludes their use as predictive markers of malignant transformation.
authors.affiliation: Department of Dermatology, Henri-Mondor Hospital, F-94010 Créteil CEDEX, France.
authors.forename: K
authors.initials: K
authors.lastname: Leroy
authors.forename: V
authors.initials: V
authors.lastname: Dumas
authors.forename: N
authors.initials: N
authors.lastname: Martin-Garcia
authors.forename: M C
authors.initials: MC
authors.lastname: Falzone
authors.forename: M C
authors.initials: MC
authors.lastname: Voisin
authors.forename: J
authors.initials: J
authors.lastname: Wechsler
authors.forename: J
authors.initials: J
authors.lastname: Revuz
authors.forename: A
authors.initials: A
authors.lastname: Créange
authors.forename: E
authors.initials: E
authors.lastname: Levy
authors.forename: L
authors.initials: L
authors.lastname: Lantieri
authors.forename: J
authors.initials: J
authors.lastname: Zeller
authors.forename: P
authors.initials: P
authors.lastname: Wolkenstein
mesh_terms: D000293:Adolescent; D000328:Adult; D001706:Biopsy; D004252:DNA Mutational Analysis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D018317:Nerve Sheath Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D009456:Neurofibromatosis 1 / Q000150:complications; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000378:metabolism; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism
chemical_list: D016159:Tumor Suppressor Protein p53